A machine learning model using existing clinical data may help clinicians screen for comorbid anxiety and depression in ...

Tolebrutinib is more effective in reducing the risk of disability progression in MS patients with paramagnetic rim lesions, ...

A detailed review of a 6-month clinical trial further reinforces strong experimental evidence that a ketogenic diet may offer ...

Combining genetic and symptom-based risk scores to predict MS may accelerate the diagnosis of the disease, according to a new ...

A new analysis provides substantial evidence that paramagnetic rim lesions drive disability in MS and are targetable with a ...

Tolebrutinib had the most protective effect against disability worsening at 6 months in patients with multiple sclerosis who had a greater number of MRI paramagnetic rim lesions at baseline, data show ...

A six-month modified Atkins diet intervention in relapsing multiple sclerosis patients led to significant immunometabolic ...

A post-hoc analysis of phase 3 trials presented at ACTRIMS Forum 2025 suggests that tolebrutinib may be more effective in MS ...

Q4 2024 Earnings Call Transcript March 3, 2025 TG Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.15, ...

Alumis Inc., a clinical stage biopharmaceutical company, announced that it will present data on its oral therapy A-005, a selective TYK2 inhibitor, at the ACTRIMS Forum 2025 on February 28 ...

Among individuals with relapsing-remitting MS, intermittent calorie restriction and ketogenic diets reduce metabolomic age.

And thanks everyone, for joining us this morning. I'm really excited, to be able to host this call just following the ACTRIMS conference that, was held last week. These meetings, are really so ...